![Ascelia Pharma: Wrap up from interview with Deputy CEO Julia Waras Brogren](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/d0b8bfb9-a57e-4d79-b406-f0df775b2e0a.png)
Ascelia Pharma
8.24 SEK -5.29%HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement. See disclaimer.
Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital. Ascelia Pharma is listed on Nasdaq Small Cap Stockholm with ticker ACE.
Read moreLatest research
Analyst
![Henrik Ekman Henrik Ekman](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://content.inderes.se/assets/6e03ef5d-f5bb-4113-a20b-1a7d036027c4.png)
![Claus Thestrup Claus Thestrup](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://content.inderes.se/assets/637ef734-dcbf-426c-bf91-0ac4a79aa71e.png)
Latest videos
Financial calendar
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Sunstone life Science Ventures Fund II K/S | 13.7 % | 14.1 % |
Avanza Pension | 8.2 % | 8.4 % |
Premium
This content is for our Premium customers only.
![Ascelia Pharma: Wrap up from interview with Deputy CEO Julia Waras Brogren](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/d0b8bfb9-a57e-4d79-b406-f0df775b2e0a.png)
![Ascelia Pharma - Commercial and partnership strategy](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/d0b8bfb9-a57e-4d79-b406-f0df775b2e0a.png)
Ascelia Pharma - Commercial and partnership strategy
![Ascelia Pharma: Podcast interview with CEO Magnus Corfitzen and CSO Andreas Norlin - Strong Orviglance data](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/d0b8bfb9-a57e-4d79-b406-f0df775b2e0a.png)
Ascelia Pharma: Podcast interview with CEO Magnus Corfitzen and CSO Andreas Norlin - Strong Orviglance data
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
PREMIUM account
![HCA Capital: Wrap up from 2024 Life Science seminar](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/ab49c0b1-56d0-4e1c-b729-6c79c89b7be2.png)
HCA Capital: Wrap up from 2024 Life Science seminar
![Life Science seminar 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/ab49c0b1-56d0-4e1c-b729-6c79c89b7be2.png)
Life Science seminar 2024
![Ascelia Pharma (One-pager): The market is still only partly discounting likelihood of approval and successful launch of Orviglance](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/d0b8bfb9-a57e-4d79-b406-f0df775b2e0a.png)
Ascelia Pharma (One-pager): The market is still only partly discounting likelihood of approval and successful launch of Orviglance
![Ascelia Pharma: Wrap up from interview Deputy CEO Julie W. Brogren](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/f269375c-f73d-444e-a01a-b723dcaa8498.png)
Ascelia Pharma: Wrap up from interview Deputy CEO Julie W. Brogren
![Ascelia Pharma - What happened during Q1?](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/d0b8bfb9-a57e-4d79-b406-f0df775b2e0a.png)
Ascelia Pharma - What happened during Q1?
Redeye: Ascelia Pharma - Time for take-off
![Ascelia Pharma, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/23e41dac-2efc-4b4e-90b9-3a7dd80ad442.png)
Ascelia Pharma, Audiocast with teleconference, Q1, 2024
Quarterly Report Q1: Primary Endpoint Met with Strong Headline Results in Orviglance Phase 3 Study
Welcome to Ascelia Pharma Investor Update: Bringing Orviglance to Patients
Bulletin from the Annual General Meeting in Ascelia Pharma AB on 6 May 2024
![Ascelia Pharma: Reaches most important milestone in company history](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/cd9fabe8-37f9-489a-8b5a-20380428cc50.png)
Ascelia Pharma: Reaches most important milestone in company history
Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study
Ascelia Pharma Draws Down SEK 15 Million Second Tranche Under Existing Loan Facility
Ascelia Pharma Reports SPARKLE Image Reading Completion and Expects Headline Results First Half of May 2024
Annual Report 2023: Solid Progress with Orviglance Phase 3 Patient Recruitment Completed and Headline Results Expected by May 2024
Notice of Annual General Meeting in Ascelia Pharma AB
![HCA Biosnack update: Biotech and Life Science stocks outperform as the general stock market moves to record highs.](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/06aef4ac-f94b-407d-ac4d-dffe67b0f7a5.png)